Skip to main content
Erschienen in: AIDS and Behavior 4/2018

25.07.2017 | Original Paper

Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants

verfasst von: Kathrine Meyers, Kristina Rodriguez, Atrina L. Brill, Yumeng Wu, Melissa La Mar, Debora Dunbar, Beryl Koblin, David Margolis, Magdalena E. Sobieszczyk, Hong Van Tieu, Ian Frank, Martin Markowitz, Sarit A. Golub

Erschienen in: AIDS and Behavior | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to identify patients’ physical and psychosocial experiences of an investigational long-acting injectable PrEP product to aid in the development of patient and provider education materials. Twenty-eight participants of a Phase 2 safety, tolerability, and acceptability study of long-acting integrase inhibitor cabotegravir (CAB-LA) were interviewed on their physical and psychosocial experiences of the injections. Five themes emerged through a framework analysis on these interview transcripts: (1) injection-related pain is highly variable across individuals; (2) pain is more impactful after the injections than during; (3) patient anxiety is critical, but does not determine the experience of injections and decreases over time; (4) intimacy and awkwardness of gluteal injections impacts patients’ experiences; (5) patient education and care strategies can mitigate the above factors. These findings can inform further sociobehavioral research within Phase 3 efficacy trials of CAB-LA, as well as patient education and provider guidance for future injectable PrEP products.
Literatur
1.
Zurück zum Zitat Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed
2.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). 2016;387(10013):53–60.CrossRef McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). 2016;387(10013):53–60.CrossRef
4.
Zurück zum Zitat Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefPubMed Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefPubMed
6.
Zurück zum Zitat Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151.CrossRef Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151.CrossRef
7.
Zurück zum Zitat Grossman H, Anderson P, Grant R, Gandhi M, Mohri H, Markowitz M, editors. Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP. HIV Research for Prevention (HIVR4P), October 2016, Chicago. Abstract OA03.06LB. Grossman H, Anderson P, Grant R, Gandhi M, Mohri H, Markowitz M, editors. Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP. HIV Research for Prevention (HIVR4P), October 2016, Chicago. Abstract OA03.06LB.
8.
Zurück zum Zitat Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. N Engl J Med. 2017;376(5):501–2.CrossRefPubMed Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. N Engl J Med. 2017;376(5):501–2.CrossRefPubMed
9.
Zurück zum Zitat Hoornenborg E, de Bree G. Acute Infection with a Wild-type HIV-1 Virus in PrEP User with High TDF Levels. CROI, February 2017, Seattle. Abstract 953.. 2017. Hoornenborg E, de Bree G. Acute Infection with a Wild-type HIV-1 Virus in PrEP User with High TDF Levels. CROI, February 2017, Seattle. Abstract 953.. 2017.
10.
Zurück zum Zitat Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29(11):1277–85.CrossRefPubMedPubMedCentral Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29(11):1277–85.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1):e28238.CrossRefPubMedPubMedCentral Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1):e28238.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.CrossRefPubMedPubMedCentral Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Meyers K, Wu E, Qian H, Huang X, H W. High degree of interest in long-acting injectable pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in two Chinese cities. 142nd APHA Annual Meeting and Exposition, November 2014, New Orleans. Abstract 305569. Meyers K, Wu E, Qian H, Huang X, H W. High degree of interest in long-acting injectable pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in two Chinese cities. 142nd APHA Annual Meeting and Exposition, November 2014, New Orleans. Abstract 305569.
14.
Zurück zum Zitat Hall EW, Heneine W, Sanchez T, Sineath RC, Sullivan P. Preexposure prophylaxis modality preferences among men who have sex with men and use social media in the United States. J Med Internet Res. 2016;18(5):e111.CrossRefPubMedPubMedCentral Hall EW, Heneine W, Sanchez T, Sineath RC, Sullivan P. Preexposure prophylaxis modality preferences among men who have sex with men and use social media in the United States. J Med Internet Res. 2016;18(5):e111.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Greene GJ, Swann G, Fought AJ, Carballo-Dieguez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2016;21(5):1336–49.CrossRef Greene GJ, Swann G, Fought AJ, Carballo-Dieguez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2016;21(5):1336–49.CrossRef
16.
Zurück zum Zitat Myers JE, Ellman TM, Westhoff C. Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention. Curr Opin HIV AIDS. 2015;10(4):271–7.CrossRefPubMed Myers JE, Ellman TM, Westhoff C. Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention. Curr Opin HIV AIDS. 2015;10(4):271–7.CrossRefPubMed
17.
Zurück zum Zitat Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Glob Health. 2013;1(2):203–12. Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Glob Health. 2013;1(2):203–12.
18.
Zurück zum Zitat Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.CrossRefPubMedPubMedCentral Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Valentino K, Poronsky CB. Human papillomavirus infection and vaccination. J Pediatr Nurs. 2016;31(2):e155–66.CrossRefPubMed Valentino K, Poronsky CB. Human papillomavirus infection and vaccination. J Pediatr Nurs. 2016;31(2):e155–66.CrossRefPubMed
20.
Zurück zum Zitat McDougal SJ, Alexander J, Dhanireddy S, Harrington RD, Stekler JD. Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington. PLoS ONE. 2014;9(8):e105030.CrossRefPubMedPubMedCentral McDougal SJ, Alexander J, Dhanireddy S, Harrington RD, Stekler JD. Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington. PLoS ONE. 2014;9(8):e105030.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Markowitz M, Frank I, Robert M. Grant, Kenneth H. Mayer, Richard Elion, Deborah Goldstein, et al. ECLAIR: a randomised phase IIA safety and pharmacokinetic study of cabotegravir long-acting injection 800 mg every 12 weeks in HIV-uninfected men. Lancet HIV. 2017 May 22. Markowitz M, Frank I, Robert M. Grant, Kenneth H. Mayer, Richard Elion, Deborah Goldstein, et al. ECLAIR: a randomised phase IIA safety and pharmacokinetic study of cabotegravir long-acting injection 800 mg every 12 weeks in HIV-uninfected men. Lancet HIV. 2017 May 22.
23.
Zurück zum Zitat Ritchie J, Spencer L. Qualitative data analsyis for applied policy research. In: Burgess R, Bryman A, editors. Analysing qualitative data. Abingdon: Taylor & Francis Books Ltd.; 1994. p. 173–94.CrossRef Ritchie J, Spencer L. Qualitative data analsyis for applied policy research. In: Burgess R, Bryman A, editors. Analysing qualitative data. Abingdon: Taylor & Francis Books Ltd.; 1994. p. 173–94.CrossRef
24.
Zurück zum Zitat Srivastava A, Thomson S. Framework analysis: a qualitiative methodology for applied policy research Journal of Administration and Governance. 2009;4(2). Srivastava A, Thomson S. Framework analysis: a qualitiative methodology for applied policy research Journal of Administration and Governance. 2009;4(2).
Metadaten
Titel
Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants
verfasst von
Kathrine Meyers
Kristina Rodriguez
Atrina L. Brill
Yumeng Wu
Melissa La Mar
Debora Dunbar
Beryl Koblin
David Margolis
Magdalena E. Sobieszczyk
Hong Van Tieu
Ian Frank
Martin Markowitz
Sarit A. Golub
Publikationsdatum
25.07.2017
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 4/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1871-x

Weitere Artikel der Ausgabe 4/2018

AIDS and Behavior 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.